as the second largest killer of women, cervical cancer is a disease that many women are very concerned about. The annual morbidity and mortality rate are very high. Recently, the first cervical cancer vaccine in mainland China, Hirsch, was approved one year later and finally announced for sale. That is to say, we can get cervical cancer vaccine in China!
On July 31, GlaxoSmithKline (GSK), a British pharmaceutical company, revealed on its website that the first approved cervical cancer vaccine in mainland China, the human papillomavirus (HPV) vaccine, has been officially launched.
Recently, the first batch of imported Hirsch has passed the inspection and release of relevant quality inspection departments in China, and now it is being supplied to the national market to meet the health needs of a large number of women of appropriate age to prevent cervical cancer through vaccination. Like other vaccines, the health institutions that provide appropriate vaccination are community hospitals and community health service centers in various cities. (this article is exclusively compiled by WYH, editor of sihai.com. If you need to reprint it, please indicate the source and source. Related article link: http://www.4hw.com.cn/life/jiankang.html)
In terms of price, GlaxoSmithKline's HPV bivalent vaccine is priced at 580 yuan (three injections are required) in mainland China. The pricing of the murshadong tetravalent vaccine is not clear. It is speculated that the price of quadrivalent vaccine in mainland China may be slightly higher than that of bivalent vaccine, about 700-900 yuan.
According to the current published pricing, the vaccination cost of 'Hirsch' in the mainland is lower than that of similar vaccines in Hong Kong. It is understood that at present, the total price of the three completed bivalent HPV vaccines in Hong Kong is about 3000 Hong Kong dollars (about 2584.4 yuan). There is little difference between the cost of bivalent and bivalent vaccines. The vaccination price of bivalent HPV vaccines is about 4000 Hong Kong dollars.
Qiao Youlin, an epidemiologist at the Institute of oncology, Chinese Academy of Medical Sciences, said: 'cervical cancer is a common cancer that seriously threatens women's health. Every year, there are 100000 new cases and 30000 deaths in China, among which the third highest incidence of cancer is among women aged 15-44. Therefore, while carrying out cervical cancer screening, cervical cancer vaccination will significantly reduce the incidence of cervical cancer and its precancerous lesions, thus reducing the burden of disease. '(this article is exclusively compiled by WYH, editor of sihai.com. If you need to reprint it, please indicate the source and source. Related article link: http://www.4hw.com.cn/life/jiankang.html)
On July 18, 2016, GSK's' Hirsch 'obtained the listing license from the State Food and Drug Administration (CFDA), becoming the first approved cervical cancer vaccine in the mainland. On May 18, this year, the cervical cancer vaccine "jiadaxiu" (human papillomavirus vaccine [16, 18, 6, 11]) developed by the US pharmaceutical company MSD company also passed the drug registration approval of CFDA and was approved in China. It is reported that "jiadaxiu" will be put on the market at the end of this year six months after being approved.
At present, Hirsch and jiadasheu are the two most widely used cervical cancer vaccines in the world, which were launched overseas in 2006 and 2009 respectively. The difference between the two is that 'Hirsch' is a bivalent cervical cancer vaccine, and 'jiadaxiu' contains two types of bivalent and bivalent vaccines. At present, the "jiadaxiu" approved in China is a tetravalent vaccine. The higher the price is, the more kinds of viruses will be covered.
According to the Research Report of Founder Securities, there are at least 10 billion markets for cervical cancer prevention. Previously, because GSK vaccine has not been listed in the mainland, nearly 2 million people come to Hong Kong for vaccination every year. (this article is exclusively compiled by WYH, editor of sihai.com. If you need to reprint it, please indicate the source and source. Related article link: http://www.4hw.com.cn/life/jiankang.html)
At present, 11 pharmaceutical companies in China have submitted clinical applications for HPV vaccine, and 7 of them (including 5 domestic and 2 imported ones that have been declared for listing) have been approved by CFDA to enter the clinical trial stage, including the nine price vaccine. Some experts predict that the launch of 'Hirsch' and the approval of 'jiadaxiu' will provide more experience for the review and approval of follow-up products, thus speeding up the process of nine price vaccine launch.
According to the public information, cervical cancer is the only female reproductive tract cancer after ovarian cancer, with nearly 600000 new cases and 300000 deaths every year in the world. In China, there are about 135000 new cases every year, of which 80000 people die. And 99.7% of cervical cancer is caused by HPV infection.
The age suitable for HPV vaccination varies from country to country, even from different institutions in the same country. Globally, the age is 9-45, and the age approved by the State Food and drug administration is 9-26.